References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

10.33667/2078-5631-2021-10-53-60

medalphabet-2065

Research Article

ДИАГНОСТИКА И ОНКОТЕРАПИЯ

DIAGNOSTICS AND ONCOTHERAPY

Таргетная терапия распространенного немелкоклеточного рака легкого с транслокацией ALK: бригатиниб расширяет наши возможности и обеспечивает успех в борьбе с прогрессированием болезни

Targeted therapy for advanced non-small cell lung cancer with ALK translocation: brigatinib expands our capabilities and ensures success in fight against disease progression

https://orcid.org/0000-0001-7728-9533

Артамонова

Е. В.

Artamonova

E. V.

Артамонова Елена Владимировна, д.м.н., зав. химиотерапевтическим отделением № 1; проф. кафедры

Artamonova Elena V., DM Sci, head of Chemotherapy Dept No. 1; prof. at Oncology and Radiotherapy Dept

ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава России; ФГAOУ ВО «Российский национальный исследовательский медицинский университет имени И. И. Пирогова» Минздрава РоссииРоссияNational Medical Research Centre of Oncology n.a. N. N. Blokhin; Russian National Research Medical University n.a. N. I. PirogovRussian Federation

2021

28062021

010

«Диагностика и онкотерапия» (1)

5360

2021

Артамонова Е.В.

Artamonova E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/2065

Статья посвящена роли и месту бригатиниба в общей стратегии лечения ALK-позитивного распространенного НМРЛ. Бригатиниб представляет собой новый мультикиназный ингибитор, который в зарегистрированной дозе 180 мг в сутки обладает чрезвычайно высокой активностью против широкого спектра мутаций ALK. У пациентов с ALK-позитивным мНМРЛ, прогрессирующим на фоне кризотиниба, бригатиниб обеспечил 16,7 месяца медианы выживаемости без прогрессирования болезни и 34,1 месяца медианы продолжительности жизни при высокой непосредственной эффективности терапии. Так, при независимой оценке данных исследования ALTA общая частота объективного ответа на бригатиниб в дозе 180 мг в сутки (после 7-дневной вводной дозы 90 мг в сутки) во второй линии таргетной терапии достигла 56 % при медиане продолжительности ответа 15,7 месяца. Важной особенностью бригатиниба является его активность в отношении интракраниальных метастазов: ЧОО со стороны измеримых метастазов в головном мозге достигла 67 %, медиана длительности ответа – 16,6 месяца, и медиана выживаемости без прогрессирования в ЦНС – 18,4 месяца. Препарат характеризуется предсказуемой и управляемой токсичностью, а предварительные данные программы раннего доступа свидетельствуют о высокой эффективности и хорошей переносимости бригатиниба российской популяцией пациентов. Планируемая в Российской Федерации регистрация бригатиниба во второй линии терапии распространенного НМРЛ с транслокацией ALK значительно расширит наши возможности в борьбе с этим грозным заболеванием.

The article explores a role of brigatinib in a basic strategy of treatment of ALK-positive non-small-cell lung cancer (NSCLC) patients with progressive disease on or with intolerance to crizotinib. Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, at an approved dose of 180 mg once daily (with 7-day lead-in at 90 mg) is associated with extremely high activity against a wide range of ALK mutations. Brigatinib demonstrate improvement in both, long-term efficacy (the median progression-free survival is 16.7 months, the median overall Survival is 34.1 months) and short-term response to treatment. Thus, in ALTA trial Brigatinib at a dose of 180 mg per day (with lead-in) in the 2nd line of targeted therapy, was associated with IRC (independent review committee)-assessed overall objective response rate of 56 % and the median duration of response of 15.7 months. Brigatinib demonstrated a high efficacy against intracranial disease: the rate of objective response in measurable brain metastases was 67 %, the median duration of response was 16.6 months, and the median progression-free survival in the central nervous system was 18.4 months. The safety profiles of brigatinib characterized by predictable and manageable toxicity. Brigatinib demonstrate the same high efficacy and good tolerability in Russian ALK+ NSCLC patients within early access programme. The expected approval of brigatinib for ALK+ NSCLC patients in the Russian Federation in the 2nd line of treatment can significantly expand our capabilities in the fight against this formidable disease.

немелкоклеточный рак легкогоALKбригатиниб

non-small-cell lung cancerALKbrigatinib

References1

GLOBOCAN 2020 https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf

Каприн А. Д., Старинский В. В., Шахзадова А. О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Москва, 2020. 252 с. Kaprin A. D., Starinskiy V. V., Shakhzadova A. O. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow, 2020. 252 p.

Rahib L., Smith B. D., Aizenberg R. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res. 2014 74 (11): 2913–21. DOI: 10.1158/0008–5472.CAN-14–0155.

Kelly K, Crowley J, Bunn PAJr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall-cell lung cancer: a Southwest Oncology Group trial. JCO 2001, 19 (13): 3210–3218.

Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346 (2): 92–98.

Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. JCO 2002; 20 (21): 4285–4291.

Belani CP; TAX 326 study group. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol. 2002; 29 (3 Suppl 12): 4–9. Review.

Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627–1639, 2015.

Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9; V 387 (N 10027): 1540–50.

Barlesi F, Park K, Ciardiello F et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. ESMO 2016 Congress, LBA44_PR.

Lee Ch. Kh., Man J., Lord S., et al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer – A Meta-Analysis. Journal of Thoracic Oncology Vol. 12, 2017, No. 2: 403–407.

Pao W, Girard N New driver mutations in non-small-cell lung cancer. The Lancet. Oncology, 01 Feb 2011, 12 (2): 175–180. DOI: 10.1016/s1470–2045(10)70087–5.

Rodig S. J., Mino-Kenudson M., Dacic S. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer. Res. 2009. Vol. 15. No. 16. P. 5216–5223.

Varella-Garcia M., Berry L. D., Su P. F. et al. ALK and MET genes in advanced lung adenocarcinomas: the Lung Cancer Mutation Consortium experience. ASCO, 2012. Abstr. 7589.

Шахпазян Н. К. Молекулярно-генетическая диагностика рака легкого. В кн. Рак легкого под ред. Лактионова К. К., Бредера В. В. М.: ГРАНАТ, 2020. с. 47–52. Shakhpazyan N. K. Molecular genetic diagnosis of lung cancer. In the book. Lung cancer ed. Laktionova K. K., Bredera V. V. M .: GRANAT, 2020. 47–52.

Solomon B. J., Mok T., Kim D. W. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer // N. Engl. J. Med. 2014. Vol. 371. № 23. P. 2167–2177.

NCCN Guidelines Version 4.2021 https://www.nccn.org/professionals/physician_gls/default.aspx#site

Клинические рекомендации МЗ РФ Злокачественное новообразование бронхов и легкого 2021 http://cr.rosminzdrav.ru/schema/30_3 Clinical guidelines of the Ministry of Health of the Russian Federation. Malignant neoplasm of the bronchi and lung 2021. http://cr.rosminzdrav.ru/schema/30_3

Camidge D. R., Pao W., Sequist L. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 11: 473–481.

Friboulet, L. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4, 662–673 (2014).

Yu-Chung Chuang, Bo-Yen Huang, Hsin-Wen Chang & Chia-Ning Yang. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity. Scientific Reports (2019) 9: 11390. https://doi.org/10.1038/s41598–019–46825–1

Doebele R. C., Pilling A. B., Aisner D. L. et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clin. Cancer Res. 2012; 18 (5): 1472–82.

Zhang S., Anjum R., Squillace R. et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to Firstand Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res 2016; 22 (22): 5527–38 (with suppl.).

Kim D-W, Tiseo M., Ahn M-J., et al. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). J Clin Oncol. 2016; 34 (suppl) [abstract 9007].

Kim DW, Tiseo M., Ahn M-J., et al. Brigatinib in Patients With Crizotinib-Refractory AnaplasticLymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 35: 2490–2498.

Camidge D. R., Kim D-W, Ahn M-J., et al., Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol 2020; 38: 1–12.

Gettinger S., Kim D-W, Tiseo M., Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials. WCLC 2016 [abstract OA08.06]. Journal of Thoracic Oncology 2017. Volume 12, Issue S 1. P S 140.

Huber R. M., Hansen K. H., Paz-Ares L., et al. Brigatinib in Crizotinib-Refractory ALK. NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology 2020, Vol. 15 No. 3: 404–415.

Kim DW, Mehra R., Tan D. S.W., et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016; 17: 452–463;

Crino L, Anh M-J, De Marinis F., et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol. 2016; 34: 2866–2873;

Shaw AT, Kim T. M., Crino L., et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017; 18: 874–886;

Camidge DR, Gadgeel Sh., Ou S-H., et al. Updated efficacy and safety data from the phase 2 NP28761 study of Alectinib in ALK-positive non-small cell lung cancer. IASLC WCLC 2016 [abstr MA07.02]. Journal of Thoracic Oncology, Volume 12 Issue S 1 January 2017. P. S 191.

Barlesi F, Dingemans A. C., Yang J. C., et al. Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol. 2016; 27 (6) suppl: abstr 2738 [1263P].

Wolf J, Helland A, Oh I-J, et al. Phase 3 ALUR study of alectinib in pretreated ALK+ NSCLC; Final efficacy, safety and targeted genomic sequencing analyses. Presented at: IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer; September 7–10, 2019; Barcelona, Spain. Abstract OA02.07.

Kris M. G., Johnson B. E., Berry L. D., et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. 2014; 311 (19): 1998–2006.

Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627–1639, 2015.

Borghaei H, Brahmer JR, Horn L, et al: Nivolumab vs docetaxel in patients with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. 2016 ASCO Annual Meeting. Abstract 9025.

Peters S, Cappuzzo F, Horn L, et al: Analysis of early survival in patients with advanced non-squamous NSCLC treated with nivolumab vs docetaxel in CheckMate 057. 2016 World Conference on Lung Cancer. Abstract OA03.05. Presented December 5, 2016.

Barlesi F, Park K, Ciardiello F et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. ESMO 2016 Congress, LBA44_PR.

Lee Ch. Kh., Man J., Lord S., et al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer – A Meta-Analysis. Journal of Thoracic Oncology Vol. 12, 2017, No. 2: 403–407.

Mazières J, Drilon A., Lusque A., et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30 (8): 1321–28.

The authors declare that there are no conflicts of interest present.